Article in NMR in biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Ines Horvat-MenihDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1373-6944
Jonathan R BirchallDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-3920-4038
Maria J Zamora-MoralesDepartment of Radiology, University of Cambridge, Cambridge, UK.
Alice BebbDepartment of Radiology, University of Cambridge, Cambridge, UK.
Joshua D KaggieDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6706-3442
Frank RiemerMohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital Helse Bergen, Bergen, Norway.
Andrew B GillDepartment of Radiology, University of Cambridge, Cambridge, UK.
Andrew N PriestDepartment of Radiology, University of Cambridge, Cambridge, UK.
Marta WylotDepartment of Radiology, University of Cambridge, Cambridge, UK.
Iosif A MendichovszkyDepartment of Radiology, University of Cambridge, Cambridge, UK.
Anne Y WarrenDepartment of Pathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
James JonesDepartment of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-2194-4903
James N ArmitageDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Thomas J MitchellDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0003-0761-9503
Grant D StewartDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0003-3188-9140
Mary A McLeanDepartment of Radiology, University of Cambridge, Cambridge, UK.
Ferdia A GallagherDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-4784-5230
Funding
Cambridge Experimental Cancer Medicine CentreCanadian Institute For Advanced ResearchCancer Research UK C19212/A16628Cancer Research UK C19212/A27150Cancer Research UK C19212/A29082Cancer Research UK EDDPMA-May22\100068Cancer Research UK Cambridge Institute, University of Cambridge C9685/A25177Cancer Research UK Cambridge Institute, University of Cambridge CTRQQR-2021\100012Mark Foundation for Cancer Research RG95043Mark Foundation Institute for Integrated Cancer MedicineNational Cancer Imaging Translational Accelerator C42780/A27066NIHR Cambridge Biomedical Research Centre BRC-1215-20014NIHR Cambridge Biomedical Research Centre NIHR203312
6 · The paper itself
Abstract
Accurate and non-invasive subtyping of localised renal tumours is an important unmet clinical challenge in uro-oncology and has significant implications for patient mortality and quality of life. Developing novel imaging methods to characterise and stratify indeterminate kidney tumours at an early stage has the potential to address this clinical challenge. Here we applied sodium MRI (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours Using · full record | OpenQuestion